TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21851618

Group type: EXPERIMENTAL
Intervention: Touch screen version of questionnaires
Number of subjects: 20

Group type: COMPARATOR
Intervention: Paper version of questionnaires
Number of subjects: 20
Study: 19526755

Group type: EXPERIMENTAL
Intervention: Astragalus Injection (AI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (Ringer's Liquid)
Number of subjects: 40
Study: 17707898

Group type: EXPERIMENTAL
Intervention: Special training program (hybrid website/CD-ROM training, seminar series, companion intervention material, clinic mobilization)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Special training program
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard training (seminar series and standard educational/self-help material)
Number of subjects: 16
Study: 15291686

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 171

Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 171
Study: 11491417

Group type: COMPARATOR
Intervention: Zidovudine (300 mg twice per day) plus Lamivudine (150 mg twice per day) plus Nelfinavir placebo (three times per day)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Zidovudine (300 mg twice per day) plus Lamivudine (150 mg twice per day) plus Nelfinavir (750 mg three times per day)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Zidovudine/lamivudine/nelfinavir (after switching from double nucleoside therapy)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Zidovudine (300 mg twice per day) plus Lamivudine (150 mg twice per day)
Number of subjects: 105
Study: 9635807

Group type: EXPERIMENTAL
Intervention: C‐arm image intensifier
Number of subjects: 197

Group type: COMPARATOR
Intervention: Conventional radiography
Number of subjects: 197
Study: 7963648

Group type: EXPERIMENTAL
Intervention: Corticosteroids applied topically immediately after UVB irradiation
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Indomethacin applied topically immediately after UVB irradiation
Number of subjects: 16
Study: 29987421

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Control (no EVT)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Follow-up infarct volume (FIV)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT) after adjustment for FIV
Number of subjects: 436
Study: 29158670

Group type: EXPERIMENTAL
Intervention: Sensory stimulation (SS)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 43
Study: 26051365

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 1106

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 1106

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly
Number of subjects: 1106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1106
Study: 23664040

Group type: EXPERIMENTAL
Intervention: Light emitting diode therapy (LEDT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 21859685

Group type: EXPERIMENTAL
Intervention: Ofatumumab 700 mg (two infusions, 2 weeks apart)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Ofatumumab 700 mg
Number of subjects: 260
Study: 17610057

Group type: EXPERIMENTAL
Intervention: Tomatis Method (Treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 0
Study: 16859505

Group type: COMPARATOR
Intervention: Recombinant activated factor VII (rFVIIa) at an initial dose of 200 microg x kg‐1 after transfusion of eight red blood cell units, followed by additional doses of 100 microg x kg‐1, one and three hours later
Number of subjects: 0
Study: 12580652

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 11193130

Group type: EXPERIMENTAL
Intervention: Withdrawal group (W), n = 21
Number of subjects: 45

Group type: COMPARATOR
Intervention: Continued medication group (C), n = 24
Number of subjects: 45
Study: 9083600

Group type: EXPERIMENTAL
Intervention: Activity Workshop
Number of subjects: 0

Group type: COMPARATOR
Intervention: Information Workshop
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peer leaders portrayed as similar
Number of subjects: 0

Group type: COMPARATOR
Intervention: Peer leaders portrayed as dissimilar
Number of subjects: 0
Study: 8473466

Group type: EXPERIMENTAL
Intervention: D‐Trp6 LHRH microcapsules (i.m. injection) at 2 months and 1 month prior to surgery
Number of subjects: 53

Group type: COMPARATOR
Intervention: No pre‐operative treatment (control group)
Number of subjects: 53
Study: 3964516

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine (0.2 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intramuscular buprenorphine (0.15 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both routes (sublingual and i.m.)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intramuscular buprenorphine
Number of subjects: 20
Study: 29776559

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan 200 mg
Number of subjects: 8432

Group type: COMPARATOR
Intervention: Enalapril 10 mg
Number of subjects: 8432
Study: 26853286

Group type: COMPARATOR
Intervention: Norepinephrine infusion
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Norepinephrine + Vasopressin (0.03 u/min)
Number of subjects: 30
Study: 24851690

Group type: EXPERIMENTAL
Intervention: CT diagnostic standard derived from Group A (n = 101) measuring size of lesion, proportion of GGO composition, long diameter, longest diameter, and size of solid component.
Number of subjects: 143

Group type: COMPARATOR
Intervention: CT diagnostic standard applied to Group B (n = 42) for evaluating accuracy.
Number of subjects: 143
Study: 22446632

Group type: EXPERIMENTAL
Intervention: Longer needle length (1 in.)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard needle length (5/8 in.)
Number of subjects: 59
Study: 20015788

Group type: EXPERIMENTAL
Intervention: Oral levofloxacin (LVFX)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Intravenous flomoxef (FMOX)
Number of subjects: 93
Study: 18805102

Group type: EXPERIMENTAL
Intervention: Preoperative coronary artery revascularization
Number of subjects: 1048
Study: 16276137

Group type: EXPERIMENTAL
Intervention: Exercise program (walking 3 d/wk and resistance exercises 2 d/wk for 40-60 minutes)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 31
Study: 12369025

Group type: EXPERIMENTAL
Intervention: Pulse oximetry measurement
Number of subjects: 803

Group type: COMPARATOR
Intervention: N/A (Control group)
Number of subjects: 803
Study: 10435729

Group type: EXPERIMENTAL
Intervention: 5 microg rhG-CSF/kg body weight plus 150 IU rhEpo/kg body weight
Number of subjects: 30

Group type: COMPARATOR
Intervention: 5 microg rhG-CSF/kg body weight
Number of subjects: 30
Study: 7607735

Group type: EXPERIMENTAL
Intervention: Methacholine (nonselective agonist)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sodium nitroprusside (endothelium-independent control)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Atropine (nonselective antagonist)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pirenzepine (M1-selective antagonist)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: AF-DX 116 (M2-selective antagonist)
Number of subjects: 16
Study: 2132424

Group type: EXPERIMENTAL
Intervention: Nisoldipine (BAY K 5552)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 50
Study: 627337

Group type: EXPERIMENTAL
Intervention: Indomethacin 3 X 25 mg orally for 5 days starting 2 days before menstruation
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 31607731

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided microwave ablation
Number of subjects: 94

Group type: COMPARATOR
Intervention: Conventional surgical excision
Number of subjects: 94
Study: 29036816

Group type: EXPERIMENTAL
Intervention: Aerobic training (AT)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Usual care plus education (CON)
Number of subjects: 71
Study: 26125443

Group type: EXPERIMENTAL
Intervention: Capecitabine and bevacizumab (CB)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Capecitabine (C)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Capecitabine and mitomycin (CBM)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: CAIRO-2 population
Number of subjects: 268
Study: 23446090

Group type: EXPERIMENTAL
Intervention: Liposome bupivacaine (66 to 532 mg)
Number of subjects: 823

Group type: COMPARATOR
Intervention: Bupivacaine HCl (75 to 200 mg)
Number of subjects: 823

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Liposome bupivacaine
Number of subjects: 823

Group type: COMPARATOR
Intervention: Bupivacaine HCl
Number of subjects: 823
Study: 20854436

Group type: EXPERIMENTAL
Intervention: Tomato paste (55 g daily, 16 mg lycopene)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Olive oil alone
Number of subjects: 20
Study: 19176726

Group type: EXPERIMENTAL
Intervention: 25En% casein diet
Number of subjects: 24
Study: 17185999

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.05‐0.6 mg/70 kg)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Fentanyl (0.075‐0.5 mg/70 kg)
Number of subjects: 74
Study: 15597592

Group type: EXPERIMENTAL
Intervention: Medtronic Freestyle (group F; n = 80)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Homograft (group H; n = 67)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Medtronic Freestyle (group F)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Homograft (group H)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 147
Study: 10937040

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 14

Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 14
Study: 9308614

Group type: EXPERIMENTAL
Intervention: 200 mg of lamotrigine 1 hour before spinal anesthesia
Number of subjects: 30
Study: 8339576

Group type: EXPERIMENTAL
Intervention: Nasotracheal intubation
Number of subjects: 300

Group type: COMPARATOR
Intervention: Orotracheal intubation
Number of subjects: 300
Study: 3555028

Group type: EXPERIMENTAL
Intervention: 750 mg of ciprofloxacin orally every 12 hours for two weeks
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 1,000 mg of ciprofloxacin orally every 12 hours for two weeks
Number of subjects: 29
Study: 30513248

Group type: EXPERIMENTAL
Intervention: Registry-based randomized clinical trial (R-RCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UCR clinical trials services
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UCR biobanking and biomarker analyses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UCR quality registries
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UCR registry platform
Number of subjects: 0
Study: 27566601

Group type: EXPERIMENTAL
Intervention: Emotional time discrimination task with emotional stimuli (neutral, positive, negative)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (normal children)
Number of subjects: 65
Study: 27218285

Group type: EXPERIMENTAL
Intervention: Pimpinella anisum‐based herbal medicine (Sinupim), 2 drops in each nostril every 12 hours for 4 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Fluticasone nasal spray, 2 puffs in each nostril every 12 hours for 4 weeks
Number of subjects: 48
Study: 24691094

Group type: EXPERIMENTAL
Intervention: Evolocumab 140 mg biweekly
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg monthly
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 614

Group type: COMPARATOR
Intervention: Ezetimibe
Number of subjects: 614

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 614
Study: 21166990

Group type: EXPERIMENTAL
Intervention: Mandibular two-implant overdentures with different attachment systems
Number of subjects: 106

Group type: COMPARATOR
Intervention: Mandibular two-implant overdentures
Number of subjects: 106
Study: 20647575

Group type: EXPERIMENTAL
Intervention: Collaborative model between physicians and pharmacists for 9 months
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Collaborative model between physicians and pharmacists for 24 months
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 27
Study: 17095130

Group type: EXPERIMENTAL
Intervention: Two doses of hepatitis B vaccine
Number of subjects: 523

Group type: COMPARATOR
Intervention: Three doses of hepatitis B vaccine
Number of subjects: 523
Study: 16298778

Group type: EXPERIMENTAL
Intervention: Fluoxetine and placebo light treatment
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Light treatment and placebo pill
Number of subjects: 78
Study: 11991015

Group type: EXPERIMENTAL
Intervention: Shellyquine (plain formulation)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dawaquin (sugar-coated formulation)
Number of subjects: 20
Study: 12555338

Group type: EXPERIMENTAL
Intervention: Naftidrofuryl
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 7759442

Group type: EXPERIMENTAL
Intervention: Normobaric hyperoxia (50% O2) for 30 min
Number of subjects: 9
Study: 2339797

Group type: EXPERIMENTAL
Intervention: Skin-surface warming below the T10 dermatome (warmed group)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No extra warming (unwarmed group)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Epidural injection of warm lidocaine (40.6 +/‐ 0.7 degrees C)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Epidural injection of cold lidocaine (16.0 +/‐ 4.7 degrees C)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Overall thermal comfort evaluation using a visual analog scale
Number of subjects: 10
Study: 431801

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Imipramine response scale
Number of subjects: 45
Study: 31774402

Group type: EXPERIMENTAL
Intervention: Gamified app intervention (n=141)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Nongamified app intervention (n=160)
Number of subjects: 301
Study: 27680896

Group type: EXPERIMENTAL
Intervention: Hierarchical model without random effects for period-within-cluster
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hierarchical model with random effects for cluster and period-within-cluster
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generalised estimating equations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unweighted cluster-level summary regression
Number of subjects: 0
Study: 26109120

Group type: EXPERIMENTAL
Intervention: High flow (HF) therapy
Number of subjects: 750

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 750
Study: 23689263

Group type: EXPERIMENTAL
Intervention: 5 mg Zn as zinc sulfate, daily for 21 days
Number of subjects: 282

Group type: COMPARATOR
Intervention: Placebo, daily for 21 days
Number of subjects: 282
Study: 21340616

Group type: EXPERIMENTAL
Intervention: Liraglutide 0.6 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 19159453

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Aspirin and Omega-3 fatty acids
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (Aspirin)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (Omega-3 fatty acids)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Aspirin and Omega-3 fatty acids placebo
Number of subjects: 100

Group type: COMPARATOR
Intervention: Aspirin placebo and Omega-3 fatty acids
Number of subjects: 100
Study: 17653751

Group type: EXPERIMENTAL
Intervention: ppV + ILM peeling
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: triamcinolone (4 mg) injection
Number of subjects: 405

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 405
Study: 15035674

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection
Number of subjects: 21

Group type: COMPARATOR
Intervention: Lateral internal sphincterotomy
Number of subjects: 21
Study: 11305510

Group type: EXPERIMENTAL
Intervention: H. pylori CagA-positive strains
Number of subjects: 60
Study: 9772056

Group type: EXPERIMENTAL
Intervention: Modified triple therapy (PCM): 40 mg pantoprazole b.i.d., 500 mg clarithromycin t.i.d., and 500 mg metronidazole t.i.d. for 7 days; followed by 40 mg pantoprazole o.d. until day 28.
Number of subjects: 286

Group type: COMPARATOR
Intervention: Dual therapy (PC): 40 mg pantoprazole b.i.d. and 500 mg clarithromycin t.i.d. for 14 days; followed by 40 mg pantoprazole o.d. until day 28.
Number of subjects: 286
Study: 7530949

Group type: EXPERIMENTAL
Intervention: Transurethral incision (TUIP)
Number of subjects: 765

Group type: COMPARATOR
Intervention: Transurethral resection (TURP)
Number of subjects: 765
Study: 3973786

Group type: EXPERIMENTAL
Intervention: Short-term prophylaxis with rectally administered diazepam for 18 months, mean of five doses per child per year
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Short-term prophylaxis with rectally administered diazepam for 18 months
Number of subjects: 289

Group type: COMPARATOR
Intervention: No prophylaxis, diazepam rectally in the event of new seizures
Number of subjects: 289

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 289
Study: 31285835

Group type: EXPERIMENTAL
Intervention: RECALL intervention (6-week classroom-based intervention targeting working memory, attention, and language skills)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Active control (existing programme)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No-intervention (education as usual)
Number of subjects: 60
Study: 29912425

Group type: EXPERIMENTAL
Intervention: SCFP at 14 g·steer‐1·d‐1
Number of subjects: 180

Group type: COMPARATOR
Intervention: SCFP at 0 g·steer‐1·d‐1 (Control)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: SCFP at 28 g·steer‐1·d‐1
Number of subjects: 180
Study: 25787121

Group type: EXPERIMENTAL
Intervention: 1% metformin gel with scaling and root planing (SRP)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo gel with scaling and root planing (SRP)
Number of subjects: 65
Study: 25201648

Group type: EXPERIMENTAL
Intervention: Feeling Better intervention (Cognitive Behavioural Therapy programme)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 36
Study: 21911258

Group type: EXPERIMENTAL
Intervention: Adjunctive oral S-adenosylmethionine (SAMe)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 20163389

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Noncontingent condition
Number of subjects: 0
Study: 18043999

Group type: EXPERIMENTAL
Intervention: Cilnidipine 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nisoldipine 10 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Head-up tilt
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Mental arithmetic test
Number of subjects: 8
Study: 17200303

Group type: EXPERIMENTAL
Intervention: Operative treatment with plate fixation
Number of subjects: 132

Group type: COMPARATOR
Intervention: Nonoperative treatment with a sling
Number of subjects: 132
Study: 15061293

Group type: EXPERIMENTAL
Intervention: 0.2 mg oral ramosetron
Number of subjects: 109

Group type: COMPARATOR
Intervention: 0.3 mg intravenous ramosetron
Number of subjects: 109
Study: 10920052

Group type: EXPERIMENTAL
Intervention: Magnetic source imaging (MSI) during printed word recognition task
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Magnetic source imaging (MSI) during spoken word recognition task
Number of subjects: 10
Study: 8970917

Group type: EXPERIMENTAL
Intervention: Relaxation training (TG)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Waiting-list control (CG)
Number of subjects: 23
Study: 1452585

Group type: EXPERIMENTAL
Intervention: Dermagraft placed beneath meshed, expanded split-thickness skin grafts (MESTSGs)
Number of subjects: 17

Group type: COMPARATOR
Intervention: MESTSGs only (control)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Dermagraft
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Dermagraft and MESTSGs
Number of subjects: 17
Study: 3881496

Group type: EXPERIMENTAL
Intervention: iopamidol
Number of subjects: 81

Group type: COMPARATOR
Intervention: Renografin‐76
Number of subjects: 81
Study: 30661439

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF) with supervised treadmill exercise
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo with supervised treadmill exercise
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF) with attention control
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo with attention control
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Exercise (both with GM-CSF and placebo)
Number of subjects: 210
Study: 28054964

Group type: EXPERIMENTAL
Intervention: 200 IU vitamin D3
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: 800 IU vitamin D3
Number of subjects: 201
Study: 26411666

Group type: EXPERIMENTAL
Intervention: C&R algorithm (Classification and Regression)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Neural Net algorithm
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: C5.0, CHAID, C&R models
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: C&R model
Number of subjects: 303
Study: 24152567

Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg twice daily (Triple)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Clopidogrel 150 mg daily (Double)
Number of subjects: 42
Study: 21367347

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate
Number of subjects: 710

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 710
Study: 19011963

Group type: EXPERIMENTAL
Intervention: Positive Behavioral Interventions and Supports (PBIS)
Number of subjects: 2596
Study: 17377212

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day within 24 hours after stroke onset (Group I, n = 18)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (not treated with simvastatin, Group II, n = 18)
Number of subjects: 36